赛伦生物 (688163)
Shanghai Serum Bio-Technology Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Sailun Biotechnology Co., Ltd.
Listing Date2022-03-11
Issue Price33.03RMB
Registered Capital1082210k RMB
Legal RepresentativeFan Zhihe
Registered AddressNo. 1288 Huaqing Road, Qingpu District, Shanghai
IndustryBiological Products
Main BusinessA biopharmaceutical enterprise specialized in the R&D, production, and sales of antiserum and antitoxin products.
Company ProfileShanghai Sailun Biotechnology Co., Ltd. was founded in 1999. It is a biopharmaceutical enterprise focused on the field of antiserum and antitoxin, dedicated to researching, developing, producing, and selling preventive and therapeutic drugs for biotoxins and biosafety.
In the field of snakebite treatment, the company possesses the only specific antivenom series products for snakebite treatment in China, meeting some emergency and urgent clinical needs in the public health sector. Furthermore, the company's antivenom is exclusively produced and sold domestically, representing a unique and proprietary product. To date, no foreign pharmaceutical company has entered this market segment in China, achieving self-reliance and control in the domestic emergency snakebite treatment field. In the field of tetanus treatment, the company has the exclusively domestically produced Equine Tetanus Immunoglobulin (F(ab')2) for the prevention and treatment of tetanus. In the field of rabies treatment, the company's Anti-Rabies Serum product is used for rabies prevention.
Simultaneously, the company possesses advanced industry capabilities in antiserum and antitoxin drug R&D, an experienced R&D team, GMP-certified production facilities, and a nationwide medical promotion team. It covers the entire industry chain from preclinical research and clinical trials to production and sales of new antiserum and antitoxin drugs, demonstrating strong competitiveness in the antiserum and antitoxin treatment field.
Stock Details
1. Key Indicators
- Total Shares(W): 734059.07
- Circulating A-Shares(W): 734059.07
- Earnings Per Share(RMB): 1.23
- Net Assets Per Share(RMB): 5.67
- Operating Revenue(W RMB): 1345261.60
- Total Profit(W RMB): 1345261.60
- **Net Profit Attributable to Parent(W RMB) **: 1345261.60
- Net Profit Growth Rate(%): -55.89
- Weighted Return on Equity(%): 4.6500
- Operating Cash Flow Per Share(RMB): 1.23
- Undistributed Profit Per Share(RMB): 1.23
- Capital Reserve Per Share(RMB): 1.23
2. Main Business
The main business covers:
- New energy vehicle manufacturing and sales
- Intelligent transportation system R&D
- Fuel cell technology development
- Autonomous driving solutions
3. Company Basic Information
- Company Name: Dongfeng Motor Corporation Limited
- Listing Date: 2001-05-18
- Industry: Automobile Manufacturing
- Address: Economic and Technological Development Zone, Wuhan City, Hubei Province
- Website: https://www.dongfeng.com.cn/
- Company Profile: The company was established with Beijing Capital Venture Group as the main sponsor....
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Securities Finance Co., Ltd. | National Team | 5,000 | 10.2 |
| 2 | China Asset Management Co., Ltd. | Public Fund | 3,200 | 6.5 |
| 3 | Hillhouse Capital Management | Private Equity Fund | 2,800 | 5.7 |
| 4 | National Social Security Fund | National Team | 2,500 | 5.1 |
| 5 | E Fund Management Co., Ltd. | Public Fund | 2,000 | 4.1 |
| 6 | China Universal Asset Management Co., Ltd. | Public Fund | 1,800 | 3.7 |
| 7 | CITIC Securities Co., Ltd. | Broker | 1,500 | 3.1 |
| 8 | Guotai Junan Securities Co., Ltd. | Broker | 1,200 | 2.4 |
| 9 | China Merchants Bank Co., Ltd. | Bank | 1,000 | 2.0 |
| 10 | ICBC Credit Suisse Asset Management Co., Ltd. | Public Fund | 900 | 1.8 |
5. Concept Sectors
- Carbon Neutrality
- Intelligent Transportation
- Fuel Cell
- Autonomous Driving
- New Energy Vehicles
- Hydrogen Energy
- Huawei Auto
- Internet of Vehicles
Remarks
- Data update date: 2025-11-02
- Data source: Public Market Information